4/A: Sana Biotechnology Director Alise Reicin Corrects Option Grant Details in Amended SEC Filing
SEC Filing (Form 4/A)
Alise Reicin, a director at Sana Biotechnology, files an amended Form 4 to correct the number of option shares acquired.
Summary
- Alise Reicin, a director of Sana Biotechnology, Inc., filed an amended Form 4 with the SEC.
- The amendment, filed on July 15, 2024, corrects a clerical error regarding the number of option shares acquired.
- The original transaction date was June 6, 2024.
- Reicin acquired options to purchase 65,000 shares of Sana Biotechnology common stock at an exercise price of $7.36.
- The options vest 100% on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
Sentiment
Score: 7
Explanation: The document is a neutral regulatory filing correcting a clerical error. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain any specific forward-looking statements regarding Sana Biotechnology's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Stakeholder Impact
- The correction ensures accurate information is available to shareholders regarding executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the original transaction (option grant). |
| 06/07/2024 | Date of original filing. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/06/2025 | Vesting date of the stock options. |
| 07/15/2024 | Date of the amended filing (Form 4/A). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.